Table 4

Adjusted hazard ratios (HRs) for discontinuation of MTX monotherapy during the first 2 years of treatment (Cox regression analysis)

HR (95% CI)*p Value
Age0.87 (0.82 to 0.93)<0.001
Male sex1.15 (0.96 to 1.38)0.12
RA diagnosis (vs PsA)1.05 (0.86 to 1.28)0.65
Disease duration1.02 (1.01 to 1.03)<0.001
Baseline patient global assessment VAS1.06 (1.01 to 1.11)0.02
Baseline MHAQ score1.26 (1.03 to 1.54)0.03
  • * HR for a 10-year increase in age, a 1-year increase in disease duration and a 10-mm increase in patient global assessment VAS.

  • MHAQ, Modified Health Assessment Questionnaire; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; VAS, visual analogue scale.